ACTINIUM PHARMACEUTICALS, INC.: 10-Q filed 2014-05-12
What ACTINIUM PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-12 (fiscal Q1 2014): 24 published measures, 62 facts as tagged in accession 0001213900-14-003153.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-05-12
- Fiscal period
- fiscal Q1 2014
- Accession
- 0001213900-14-003153 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACTINIUM PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 6,559,906 | USD | |
| At 2013-12-31 | 5,765,675 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | -13,468,145 | USD | |
| At 2013-12-31 | -1,559,545 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 5,877,781 | USD | |
| At 2013-12-31 | 5,533,366 | USD | |
| At 2013-03-31 | 3,239,886 | USD | |
| At 2012-12-31 | 5,618,669 | USD | |
| At 2011-12-31 | 5,703,798 | USD | |
| At 2010-12-31 | 196,135 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -16,699,497 | USD | 90 |
| 2000-06-14 to 2014-03-31 | -83,216,752 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | -689,027 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -2,490,948 | USD | 90 |
| 2000-06-14 to 2014-03-31 | -53,186,022 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | -2,312,338 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,699 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 833,950 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 1,112 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 2,837,062 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 62,897,753 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | -65,333 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -1,699 | USD | 90 |
| 2000-06-14 to 2014-03-31 | -3,833,950 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | -1,112 | USD | 90 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 14,214 | USD | |
| At 2013-12-31 | 13,920 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -4,138,426 | USD | 90 |
| 2000-06-14 to 2014-03-31 | -65,468,460 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | -2,022,964 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 6,545,692 | USD | |
| At 2013-12-31 | 5,751,755 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2000-06-14 to 2014-03-31 | 1,967,215 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 575 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 20,028,051 | USD | |
| At 2013-12-31 | 7,325,220 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 4,138,426 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 65,468,460 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 2,022,964 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 2,460,968 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 31,548,346 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 1,085,707 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 25,562,346 | shares | |
| At 2013-12-31 | 24,565,447 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 69,723,045 | USD | |
| At 2013-12-31 | 64,933,145 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 17,179 | USD | |
| At 2013-12-31 | 15,480 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 2,965 | USD | |
| At 2013-12-31 | 1,560 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 667,911 | USD | |
| At 2013-12-31 | 218,389 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,676,053 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 30,100,379 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 933,135 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,405 | USD | 90 |
| 2013-01-01 to 2013-03-31 | 0 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 1,405 | USD | 90 |
| 2000-06-14 to 2014-03-31 | 3,265,427 | USD | 5039 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -12,561,071 | USD | 90 |
| 2000-06-14 to 2014-03-31 | -17,748,292 | USD | 5039 |
| 2013-01-01 to 2013-03-31 | 1,333,937 | USD | 90 |
Inspect the source
- Entity
- ACTINIUM PHARMACEUTICALS, INC. / CIK 0001388320
- Captured
- 2026-09-20T07:59:08.087Z
- SEC response SHA-256
8b2cf9a9df391f2441e59da237c67a180665686e2082a76d5298eb6715d76292
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001388320.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))